Robert W. Baird initiated coverage on Intra-Cellular Therapies with a new price target
$ITCI
Biotechnology: Pharmaceutical Preparations
Health Care
Robert W. Baird initiated coverage of Intra-Cellular Therapies with a rating of Outperform and set a new price target of $83.00